LatticeworkTHE EVIDENCE DESK
← Discover companies

Investigate / reported ownership

XENE

Xenon Pharmaceuticals Inc

2 tracked reported owners · snapshot updated 2026-10-04. Delayed disclosures, not live holdings or an investment recommendation.

Revisit Saved →

Who reports owning XENE?

Select a manager to inspect their portfolio. Reports may cover different quarters; portfolio weights describe disclosed long 13F holdings, not total economic exposure.

Sort↑

Go beyond ownership.

A reviewed company brief is not available yet. You can inspect reported owners above and their filings below, then save this company for further research.

We have not generated a business case or inferred manager motives from these holdings.

Filing dates and original SEC sources

Your research workspace / XENE

Ask better questions. Keep the evidence.

Explore the available sources for XENON PHARMACEUTICALS INC, then keep what deserves another look.

Ownership-only coverage · Ownership snapshot 2026-10-04. Not live analysis.

01 Investor activity

Reported evidence

Who reports owning it?

2 tracked reported owners in the snapshot generated 2026-10-04. Reports can cover different quarters. These are delayed disclosures, not live positions, total economic exposure, endorsements or reasons for investing.

Inspect reported owners and filing dates →

02 Business evidence

No reviewed company brief is available. Business results, case and risks have not been established here.

03 Questions to investigate

A question is a starting point—not a finding. Choose one to inspect its evidence.

AI pilot: four questions per browser across all stocks every 48 hours, starting with your first attempt. Suggested questions and source search are unlimited. Failed attempts may count. A shared-network safety limit also applies.

AI questions are currently unavailable. Source search and suggested questions work without a model.

Uses this company’s dated evidence, not live web research. AI selects passages; it does not invent new claims or evaluate whether to invest. Don’t enter private information. Questions are not saved to your account.

Open saved takeaways →

Keep your next step small.

Save the company and inspect its evidence. Recording a private view is optional and requires a separate, explicit save.

Record my own view →
Optional email follow

Latticework Follow

Follow XENE

Email me only when a reviewed weekly edition contains a material new decision about XENE: a new position, exit, or a large share-count change that also clears the size threshold. There may be quiet weeks.

Confirm by email. Manage or stop follows in one click. See our privacy notice.

Long US 13F disclosures omit shorts and can be amended. CUSIP 98420N105. No current price, valuation or manager motive is inferred.